Over the years, our group has developed expertise in essential processes to serve global consumers with highly innovative and effective products. This enables us to deliver exceptional quality and reliability as an innovator and manufacturer.
We deliver high-quality and safe generic drugs to 39 countries across four continents, driven by the rapid generic drug development and reliable contract research services.
Cutting-edge research and development, systematic scaling up, contract manufacturing to optimize overall productivity, thorough clinical trials for additional safety evaluation, and solid commercial manufacturing, all in a well-defined step-by-step process.
Analytical method development and validation helps in getting accurate results and critical assessment of product-specific acceptance criteria.
We identify product potential, based on which we develop innovative process solutions. We then take care of the product approvals, finally ending with ANDA filing with the FDA.
We have developed cost-effective yet highly efficient ways to develop IP oriented formulations. We also make the development of process technologies economical.
Our experienced regulatory teams conduct regular quality checks throughout the developmental process to ensure that our complicated generics are effective and safe. Robust API manufacturers back our Formulation Development, making sure our supply chain is reliable and unhindered in the long run.
We have efficient development capability to produce Novel Drug Delivery Systems along with Para IV, NCE-1 and 505 B2.
We manufacture oral solids in the form of tablets and capsules at our state-of-the-art US FDA plant in Atlanta, USA.
| Dosage Forms | Per Month |
|---|---|
| Tablets | 80 million |
| Capsules | 70 million |
Our manufacturing plant at Ahmedabad, India is highly modern and advanced, with a massive production capability. We produce Small Vial Parenterals, Oral Solids & Liquids, Beta Lactum, and Cephalosporins SVP in millions every month, managed by an expert team.
| Dosage Forms | Per Month |
|---|---|
| Ampoules | 2 million |
| Liquid Vials | 2 million |
| Dry Powder Vials | 1.25 million |
| Lyophilized Vials | 0.2 million |
| Dosage Forms | Per Month |
|---|---|
| Tablets | 62.5 million |
| Capsules | 12.5 million |
| Dry Powder | 0.50 million |
| Oral Liquid | 0.625 million |
| Dosage Forms | Per Month |
|---|---|
| Tablets | 5 million |
| Capsules | 12.5 million |
| Dry Powder | 5 million |
| Dosage Forms | Per Month |
|---|---|
| Ampoules | 2 million |
| Liquid Vials | 2 million |
© Ratnatris Pharmaceuticals. All Rights Reserved. 
